Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary

Passage Bio, Inc. (PASG) reported a quarter ended 2026 with comprehensive loss and net loss of $7.82M, compared with $9.39M a year earlier, and diluted loss per share of $2.44 versus $2.96. The company said it signed a merger agreement with Remix, expects closing in Q4 2026 with $100M financing, is winding down AAV programs, and has $24.2M cash as of June 30, 2026.

Original reporting
Published Aug 10, 2026, 11:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary — source image
Decision brief

The 30-second read

$PASGBearishMed
01

Why it matters

Traders should focus on liquidity (cash runway), deal execution (merger approvals and Q4 2026 closing), and the operational reset (AAV program wind-down and license out/transfer activity).

02

Market read

A single filing bundles losses, restructuring progress, gene-therapy wind-down, and a merger closing/liquidity dependency, which can drive valuation and dilution expectations.

03

What to watch

The article does not quantify expected post-merger cash burn, probability of approvals, or financing terms beyond the $100M headline, which could materially change risk.

Relevance 7/10Novelty 6/10Timing: 10-Q filed today, liquidity and merger closing timeline disclosed

Background

Passage BIO’s 10-Q summarizes quarterly financial results and multiple corporate actions, including a planned merger and operational restructuring.

Company-level read

Ticker impact

$PASGBearishMedium confidence
Context

Passage BIO reported a 10-Q with a $7.82M net loss and disclosed a merger agreement with Remix plus a $100M financing plan.

Expected impact

Near-term downside bias as liquidity runway is constrained and operations depend on merger closing or new financing.

Evidence & confidence

The article’s newest facts are the quarter’s loss figures, the merger agreement timing (closing expected Q4 2026), and the stated cash runway of $24.2M as of June 30, 2026.

Market effects

Highlights ongoing biotech cost cutting and program wind-downs, reinforcing sector-wide financing and execution risk for gene-therapy developers.

No clear regional spillover beyond US microcap biotech sentiment.

Limited global relevance; primarily company-specific liquidity and deal execution.

Counterpoint

The merger and $100M financing could extend runway and accelerate a pipeline transition, potentially reducing long-term dilution risk if approvals proceed.

Key entities

  • Passage BIO, Inc.

    Reported quarterly comprehensive loss and disclosed merger, restructuring, and program wind-down details in its 10-Q.

  • Remix

    Merger agreement counterparty; closing expected in Q4 2026 subject to approvals and concurrent $100M financing.

  • Catalent

    Named in the wind-down as part of terminated manufacturing, collaboration, and license agreements.

  • Gemma

    Named in the wind-down and pipeline transition via out-licensing and research transfer.

  • University of Pennsylvania

    Named in the pipeline transition and partial termination of PBFT02 license rights to Penn for FTD-GRN.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

$ASTSMed

AST SpaceMobile Sinks 8% as New Offering Filing Revives Dilution Fears

AST SpaceMobile (ASTS) fell 8% after filing for a new securities sale, raising dilution concerns. The company's share count rose from 200M to 300M between late 2024 and Q3 2026. AT&T (T) and Vodafone (VOD), which have stakes in AST, are also affected. AST's free cash flow was negative $1.8B over the last four quarters, with analysts expecting negative free cash flow through 2028.

$MKLMed

The Board of Directors (the Board) of Markel Group Inc. (the Company) approved a $2.5 billion increase to the Company's existing $2.0 billion share…

MARKEL GROUP INC. (MKL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 18, 2026, the Board of Directors (the Board) of Markel Group Inc. (the Company) approved a $2.5 billion increase (the "Additional Authorization") to the Company's existing $2.0 billion share repurchase authorization (the "Existing Authorization